The differential expression of a large number of mTOR-dependent genes in both the limbic (112/1165, 9.6%) and neocortical stage AD (176/1165, 15.1 %) indicates that the disruption of these molecular pathways is not merely a consequence of the pathology and implies that the dysregulation of the downstream pathways of mTOR may play an important and early role in the development of AD. The gene discussed is MTOR; the disease is Alzheimer disease.